NAV

Sodium phosphate, monobasic, unspecified form

Identification

Summary

Sodium phosphate, monobasic, unspecified form is an osmotic laxative used to cleanse the colon before a colonoscopy.

Brand Names
Fleet Mineral Oil, Pedia-lax Liquid, Urogesic Blue Reformulated Apr 2012
Generic Name
Sodium phosphate, monobasic, unspecified form
DrugBank Accession Number
DB14503
Background

Not Available

Type
Small Molecule
Groups
Approved
Synonyms
Not Available
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Used to treat constipation or to clean the bowel before a colonoscopy Label.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofConstipation••• •••
Used in combination for symptomatic treatment ofOccasional constipationCombination Product in combination with: Sodium phosphate, dibasic, unspecified form (DB14504)••• ••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Sodium phosphate inceases fecal water content to increase mobility through the large intestine 1.

Mechanism of action

Sodium phosphate is thought to work by increasing the amount of solute present in the intestinal lumen thereby creating an osmotic gradient which draws water into the lumen 1.

Absorption

Tmax for phosphate absorption with orally administered liquid sodium phosphate is 1-3h 3.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Intamuscular LD50 of 250mg/kg and oral LD50 of 8290 mg/kg reported in rats 7. Phosphate toxicity is likely due to the disturbance of other electrolytes when phosphate levels are high, producing symptoms including tetany, dehydration, hypotension, tachycardia, hyperpyrexia, cardiac arrest and coma 4. Risk of raising phosphate levels through use of sodium phosphate appears to be higher in smaller patients 3.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcetazolamideThe risk or severity of dehydration can be increased when Acetazolamide is combined with Sodium phosphate, monobasic, unspecified form.
AclidiniumThe therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Aclidinium.
AlfentanilThe therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Alfentanil.
AlloinThe risk or severity of adverse effects can be increased when Sodium phosphate, monobasic, unspecified form is combined with Alloin.
AlmasilateThe therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Almasilate.
Food Interactions
  • Take with a full glass of water.
  • Take with food.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Active Moieties
NameKindUNIICASInChI Key
Sodium cationionicLYR4M0NH3717341-25-2FKNQFGJONOIPTF-UHFFFAOYSA-N
Phosphoric acidunknownE4GA8884NN7664-38-2NBIIXXVUZAFLBC-UHFFFAOYSA-N
Phosphate ionionicNK08V8K8HR14265-44-2NBIIXXVUZAFLBC-UHFFFAOYSA-K
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Care One EnemaSodium phosphate, monobasic, unspecified form (19 g/118mL) + Sodium phosphate, dibasic, unspecified form (7 g/118mL)EnemaRectalAmerican Sales Company2010-01-182014-06-07US flag
Curad Oral Saline LaxativeSodium phosphate, monobasic, unspecified form (7.2 g/15mL) + Sodium phosphate, dibasic, unspecified form (2.9 g/15mL)LiquidOralMedline Industries2012-07-162016-12-31US flag
Curad Oral Saline LaxativeSodium phosphate, monobasic, unspecified form (7.2 g/15mL) + Sodium phosphate, dibasic, unspecified form (2.9 g/15mL)LiquidOralMedline Industries2012-07-162016-12-31US flag
Curad Saline LaxativeSodium phosphate, monobasic, unspecified form (19 g/118mL) + Sodium phosphate, dibasic, unspecified form (7 g/118mL)EnemaRectalMedline Industries, Inc.2012-07-162017-01-01US flag
CVS PharmacySodium phosphate, monobasic, unspecified form (19 g/118mL) + Sodium phosphate, dibasic, unspecified form (7 g/118mL)EnemaRectalCVS PHARMACY2013-03-08Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
DarcalmaSodium phosphate, monobasic, unspecified form (40.8 mg/1) + Hyoscyamine sulfate dihydrate (.12 mg/1) + Methenamine (81.6 mg/1) + Methylene blue trihydrate (10.8 mg/1) + Phenyl salicylate (36.2 mg/1)TabletOralKylemore Pharmaceuticals, LLC2009-12-012009-12-02US flag
DarcalmaSodium phosphate, monobasic, unspecified form (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (81.6 mg/1) + Methylene blue trihydrate (10.8 mg/1) + Phenyl salicylate (36.2 mg/1)TabletOralRiver's Edge Pharmaceuticals, LLC2008-12-222011-07-31US flag
OroMinSodium phosphate, monobasic, unspecified form (0.056 g/100g) + Calcium chloride dihydrate (0.054 g/100g) + Sodium fluoride (0.01 g/100g)RinseDentalGermiphene Corporation2017-06-16Not applicableUS flag
Uro-BLUESodium phosphate, monobasic, unspecified form (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (81.6 mg/1) + Methylene blue trihydrate (10.8 mg/1)TabletOralMethod Pharmaceuticals2014-12-012015-07-06US flag
Urogesic BlueSodium phosphate, monobasic, unspecified form (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (81.6 mg/1) + Methylene blue trihydrate (10.8 mg/1)TabletOralEdwards Pharmaceuticals, Inc2010-04-302017-12-30US flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
3980JIH2SW
CAS number
Not Available

References

General References
  1. Rex DK: Dosing considerations in the use of sodium phosphate bowel preparations for colonoscopy. Ann Pharmacother. 2007 Sep;41(9):1466-75. Epub 2007 Jul 24. [Article]
  2. Schanz S, Kruis W, Mickisch O, Kuppers B, Berg P, Frick B, Heiland G, Huppe D, Schenck B, Horstkotte H, Winkler A: Bowel Preparation for Colonoscopy with Sodium Phosphate Solution versus Polyethylene Glycol-Based Lavage: A Multicenter Trial. Diagn Ther Endosc. 2008;2008:713521. doi: 10.1155/2008/713521. [Article]
  3. Ehrenpreis ED: Increased serum phosphate levels and calcium fluxes are seen in smaller individuals after a single dose of sodium phosphate colon cleansing solution: a pharmacokinetic analysis. Aliment Pharmacol Ther. 2009 Jun 1;29(11):1202-11. doi: 10.1111/j.1365-2036.2009.03987.x. Epub 2009 Feb 27. [Article]
  4. Razzaque MS: Phosphate toxicity: new insights into an old problem. Clin Sci (Lond). 2011 Feb;120(3):91-7. doi: 10.1042/CS20100377. [Article]
  5. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
  6. FDA Guide: Sodium Phosphate Tablet [Link]
  7. ChemIDPlus: Sodium Phosphate [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Unknown StatusTreatmentMalnutrition1
2CompletedTreatmentAcute Malnutrition, Severe Acute Malnutrition / Sickle Cell Anemia1
1CompletedNot AvailableHealthy Volunteers (HV)1
1CompletedTreatmentType 1 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral
LiquidRectal
SolutionIntravenous
KitIntravenous
LiquidOral
RinseDental
EnemaRectal
Tablet, coatedOral
CapsuleOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Transporters

Details1. Sodium-dependent phosphate transporter 1
Kind
Protein
Organism
Humans
Pharmacological action
No
General Function
Not Available
Specific Function
Not Available
Gene Name
SLC20A1
Uniprot ID
Q8WUM9
Uniprot Name
Sodium-dependent phosphate transporter 1
Molecular Weight
73699.01 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
Details2. Sodium-dependent phosphate transporter 2
Kind
Protein
Organism
Humans
Pharmacological action
No
General Function
Virus receptor activity
Specific Function
Sodium-phosphate symporter which seems to play a fundamental housekeeping role in phosphate transport by absorbing phosphate from interstitial fluid for normal cellular functions such as cellular m...
Gene Name
SLC20A2
Uniprot ID
Q08357
Uniprot Name
Sodium-dependent phosphate transporter 2
Molecular Weight
70391.755 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
Details3. Sodium-dependent phosphate transport protein 2A
Kind
Protein
Organism
Humans
Pharmacological action
No
General Function
Sodium:phosphate symporter activity
Specific Function
Involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 70-80% of the apical influx.
Gene Name
SLC34A1
Uniprot ID
Q06495
Uniprot Name
Sodium-dependent phosphate transport protein 2A
Molecular Weight
68936.53 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
Details4. Sodium-dependent phosphate transport protein 2B
Kind
Protein
Organism
Humans
Pharmacological action
No
General Function
Sodium:phosphate symporter activity
Specific Function
May be involved in actively transporting phosphate into cells via Na(+) cotransport. It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the s...
Gene Name
SLC34A2
Uniprot ID
O95436
Uniprot Name
Sodium-dependent phosphate transport protein 2B
Molecular Weight
75758.535 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
Details5. Sodium-dependent phosphate transport protein 2C
Kind
Protein
Organism
Humans
Pharmacological action
No
General Function
Sodium:phosphate symporter activity
Specific Function
May be involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 20-30% of the apical influx.
Gene Name
SLC34A3
Uniprot ID
Q8N130
Uniprot Name
Sodium-dependent phosphate transport protein 2C
Molecular Weight
63548.94 Da
References
  1. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. [Article]

Drug created at July 11, 2018 17:37 / Updated at January 08, 2021 01:07